Key Highlights: Implications: Obeda gives Dr. Reddy’s a second GLP‑1 foothold in India, but this time in the much bigger day‑to‑day diabetes market, not just injectable semaglutide. Because it ...
Key Highlights: Implications: Zydus is differentiating in a crowded GLP‑1 space with a single reusable multi‑dose pen and 15 mg/3 mL cartridge, simplifying titration and potentia...
Key Highlights: Implications: Anyra smashes Eylea pricing barriers, flooding retina clinics with budget-friendly therapy that keeps patients compliant for years. Zydus seizes op...
Key Highlights: Implications: Tishtha detonates pricing bombs on Roche’s Tecentriq and MSD’s Opdivo, handing cash-strapped hospitals a lifeline while exploding p...
